Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently…
Continuous Kesimpta ® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study 1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population 2 Switch from teriflunomide to Kesimpta resulted in significant...
Nasdaq GlobeNewswire
17/04/2024
Press Release: New 48-week frexalimab phase 2 data support potential for high…
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisData support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary...
Nasdaq GlobeNewswire
17/04/2024
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholdersAllschwil, Switzerland – April 17, 2024Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at...
Nasdaq GlobeNewswire
17/04/2024
Global Dental Lasers Market to Witness Upsurge in Growth at a CAGR of ~5% by…
Key Takeaways from the Dental Lasers Market Report Key Takeaways from the Dental Lasers Market Report To read more about the latest highlights related to the dental lasers market, get a snapshot of the key highlights entailed in theGlobal Dental Lasers Market Report Dental Lasers Overview Dental lasers have revolutionized the field of dentistry, offering a precise and minimally invasive alternative to traditional dental tools. These focused beams of light energy can be used...
PR Newswire
16/04/2024
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn)…
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process...
Nasdaq GlobeNewswire
16/04/2024
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement…
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1's potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational...
Nasdaq GlobeNewswire
16/04/2024
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in…
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration /2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus,...
Nasdaq GlobeNewswire
16/04/2024
Growth of 28% of 2024 first quarter revenue
Press release Ecully, April 16, 2024 – 8 p.m. First-quarter 2024 revenue of €3.1 millionGrowth of 28% compared with 2023 first quarter In thousands of euros 20242023Change 2023/2022Q1 revenue 3,0702,398+28%Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €3.1 million in the first quarter of 2024, an increase of 28% compared with the same period...
Nasdaq GlobeNewswire
16/04/2024
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong…
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong, recognizing French innovation in Asia PacificClermont-Ferrand, France, Tuesday 16 April 2024 (6.30pm CET) CARBIOS(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, was awarded 1st prize in the "So French So Innovative" Award organized by Business France, the Hong Kong Committee of French Foreign…
Nasdaq GlobeNewswire
16/04/2024
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024– Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors' proposal to transfer the Company's result to 2024 was also adopted.The Remuneration Report for 2023 was approved.The Board of Directors and the Board of Management were discharged from liability.Luc Debryune, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter and...
Nasdaq GlobeNewswire
16/04/2024
Groupe Casino - Nombre de droits de vote et d'actions au 31-03-2024
CASINO, GUICHARD-PERRACHON Société anonyme au capital de 373 040 807,35 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 mars 2024(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables...
Nasdaq GlobeNewswire
16/04/2024
OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody…
OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes EffectiveNANTES, France, April 16, 2024 – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently...
Nasdaq GlobeNewswire
16/04/2024
VIRBAC: Building on the momentum of the second half of 2023, strong…
KEY FIGURES Revenue1 stquarter 2024 € 345.7MGrowth at constant exchange rates and scope 1 +9.7%of whichcompanion animals +16.2% farm animals +1.2%Growth at constant exchange rates +10.8% Overall change +9.8% 1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the...
Nasdaq GlobeNewswire
16/04/2024
Human Identification Market Worth $1.3 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100607777 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100607777 Browse in-depth TOC on "Human Identification Market" 262 - Tables 42 - Figures 242 - Pages Human Identification Market Scope: In 2023, the consumables segment held the largest share of the human identification market by product segment. Based on product, the...
PR Newswire
16/04/2024
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3%…
Prime Determinants of Growth Prime Determinants of Growth The emphysema treatment market has experienced significant growth owing to rise in prevalence of emphysema cases globally. Furthermore, rise in number of smokers has contributed in the increasing prevalence of emphysema. In addition,Asia-Pacificis expected to present significant opportunities for growth owing to rise in awareness programs for emphysema, increasing diagnosis and increase in investments for well-developed...
PR Newswire
16/04/2024
Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market…
Asthma is a chronic inflammatory respiratory disease, which affects adults as well as pediatrics. In the United States, it affects approximately 25 million people, including 5 million children/adolescents. About 1 million asthmatic people in the United States get hospitalized each year. Globally, asthma impacts more than 250 million people, reflecting high disease burden. In addition to the age-group, asthma patients can be categorized into mild, moderate or severe patients, based on the disease…
PR Newswire
16/04/2024
The Nomination Committee's proposal for the election of Board members and…
The Nomination Committee proposes that Eugen Steiner, Cecilia Edström, Pär Gellerfors, Lars Lannfelt, Lotta Ljungqvist and Mikael Smedeby be re-elected as board members and that Anna-Lena Engwall be elected as new board member, each for a term of office until the end of the next annual general meeting. Furthermore, the Nomination Committee proposes that Eugen Steiner be re-elected as chairperson. The Nomination Committee proposes thatEugen Steiner, Cecilia Edström, Pär Gellerfors, Lars...
PR Newswire
16/04/2024
TATAA Biocenter Achieves GLP Accreditation for qPCR and dPCR
The demand for these services is driven by the over 2500 cell and gene therapies being developed in the United States and Europe and the progress of technologies involving CRISPR, AAV vectors, and mRNA therapeutics. These innovations require rigorous molecular analyses and adherence to regulated guidelines for bioanalysis and safety testing, including biodistribution, pharmacokinetics, transgene expression, and shedding throughout the developmental stages of therapies. The demand for these...
PR Newswire
16/04/2024
CSafe Elevates Cell and Gene Therapy Transport with Reusable Cryogenic Solution
"The cell and gene therapy industry needs more solutions that integrate data with products, alongside a global network with advanced capabilities and service infrastructure," said Patrick Schafer, CSafe CEO. "Our team has worked tirelessly to develop these new solutions to ensure the integrity of our customers' valuable cargo, and ultimately provide peace of mind." "The cell and gene therapy industry needs more solutions that integrate data with products, alongside a…
PR Newswire
16/04/2024
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for…
SOLANA BEACH, Calif., April 16, 2024 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain (GB) with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that…
PR Newswire
16/04/2024
INSIGHTEC ANNOUNCES EXABLATE PRIME AVAILABILITY IN EUROPE -THE NEXT GENERATION…
Like its predecessor, Exablate Prime enables incisionless neurosurgery as an outpatient procedure to provide relief to people living with movement disorders, such as essential tremor and Parkinson's disease. New improvements include an enriched user interface and enhancements to optimize productivity. Specific improvements include: Like its predecessor, Exablate Prime enables incisionless neurosurgery as an outpatient procedure to provide relief to people living with movement disorders, such…
PR Newswire
16/04/2024
IMC to transfer its Oranim Pharmacy shares back to the seller
About IM Cannabis Corp. About IM Cannabis Corp. IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company has recently exited operations inCanadato pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets,IsraelandGermany. The Company leverages a transnational ecosystem powered by...
PR Newswire
16/04/2024
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial…
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and...
Nasdaq GlobeNewswire
16/04/2024
Vistin Pharma ASA: Invitation to Q1 2024 conference call
Vistin Pharma ASA will release its first quarter results on Wednesday 24 thof April 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 24 thof April at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The first quarter conference call will be available via web and audio through the following access points: Webcast: https://edge...
Nasdaq GlobeNewswire
16/04/2024
Altri Comunicati